Background
==========

Vitamin D deficiency in patients with chronic obstructive pulmonary disease (COPD) is highly prevalent and associated with disease severity.[@b1-copd-12-2583],[@b2-copd-12-2583] Although vitamin D is classically known for its function in calcium and bone metabolism, studies in the past decades have suggested a far broader range of physiological effects of vitamin D, including effects on muscle function and the immune system, linked to the presence of vitamin D receptors (VDR) on the cells of these tissues.[@b3-copd-12-2583] These effects might have clinical implications for patients with COPD.[@b4-copd-12-2583]

Impaired muscle function and poor physical performance form a major part of the disease burden in patients with COPD.[@b5-copd-12-2583] Quadriceps and handgrip weakness as well as poorer score in the 6-minute walking test are predictors of increased mortality risk in COPD patients.[@b6-copd-12-2583]--[@b8-copd-12-2583] In the general population, several meta-analyses of randomized clinical trials have shown positive effects of vitamin D supplementation on muscle strength and physical performance.[@b9-copd-12-2583]--[@b11-copd-12-2583] This effect was larger in participants with severe vitamin D deficiency at baseline.[@b11-copd-12-2583],[@b12-copd-12-2583] Observational studies on the relationships between vitamin D status and muscle function in COPD patients are controversial, although a polymorphism in the VDR gene has been shown to affect quadriceps muscle strength.[@b5-copd-12-2583],[@b13-copd-12-2583],[@b14-copd-12-2583] Only two intervention studies have been carried out in COPD patients without vitamin D deficiency selection. These studies were too small to perform post hoc analyses in deficient groups. Therefore, there is a need to specifically study COPD patients with vitamin D deficiency.

Besides muscle strength and physical function, some observational studies have shown that serum 25-hydroxyvitamin D (25(OH)D) concentrations are positively associated with pulmonary function.[@b15-copd-12-2583],[@b16-copd-12-2583] One hypothesis for this relationship is that vitamin D might affect pulmonary function through beneficial effects on muscle strength:[@b5-copd-12-2583] worse muscle function might lead to impaired respiratory muscle strength and thus poor pulmonary function.

These findings have led us to the question of whether vitamin D supplementation might influence disease course through an effect on muscle function in COPD patients. Vitamin D might be an attractive treatment option, as it is easy, safe, and inexpensive. With this study, we aim to assess the effects of vitamin D supplementation on respiratory muscle strength and physical performance specifically in vitamin D-deficient COPD patients. In addition, we assess its effects on pulmonary function, hand grip strength, exacerbation rate, and quality of life.

Methods
=======

Study design and participants
-----------------------------

We performed a randomized placebo-controlled trial in two centers. Participants were recruited from the departments of pulmonary disease of a university medical center (VU University Medical Center) and a large teaching hospital (Northwest Hospital group) in the period 2012--2014. Patients with COPD who met the inclusion criteria were asked to participate in the study ([Table 1](#t1-copd-12-2583){ref-type="table"}). If patients agreed to participate, their serum 25(OH)D concentration was assessed. Patients who had a vitamin D deficiency (25(OH)D \<50 nmol/L) were included in the study. Study visits took place at baseline and after 3 and 6 months. All participants provided written informed consent. The study was approved by the local medical ethics committee of the VU University Medical Center and Northwest Hospital group (NL36386.029). The study was registered in the Netherlands Trial Register (NTR2827).

Randomization and masking
-------------------------

Participants were allocated by computer-generated block randomization (blocks of four patients) to receive either vitamin D or placebo with stratification by gender and institution. Pharmacists of the VU University Medical Center, who were independent from the clinical study team, performed the allocation. After the last participant completed the study, masking continued until all analyses were performed.

Intervention
------------

Participants received either 1,200 IU colecalciferol or a matching placebo during 6 months according to randomization. They were allowed to use vitamin D supplementation to a maximum of 400 IU/day, as advised by the Dutch Health Council for adults aged \<70 years. During the study, the participants were advised to ensure a dietary calcium intake of at least 1,000 mg per day. If this was not feasible, they received calcium supplementation to ensure a total calcium intake of 1,000 mg/day, as advised by the Dutch Health Council.

Outcomes
--------

### Primary outcomes

Primary outcomes were respiratory muscle strength and physical performance. Respiratory muscle strength was assessed by measuring maximal inspiratory and expiratory pressure according to American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines.[@b17-copd-12-2583] Physical performance score was assessed by the tandem test, chair stands test, 3-m walking test, and 6-minute walking test.[@b18-copd-12-2583],[@b19-copd-12-2583] The tandem test is a measure which estimates balance. The chair stands test largely represents quadriceps muscle strength as well as balance and the 3-meter walking test depicts a combination of gait performance and balance. The 6-minute walking test measures general functional exercise capacity.

### Secondary outcomes

Secondary outcomes in this study were forced expiratory volume in 1 second and forced vital capacity measured by spirometry according to ATS/ERS guidelines,[@b20-copd-12-2583] peak expiratory flow determined using the Mini-Wright peak flow meter, handgrip muscle strength measured using a dynamometer,[@b21-copd-12-2583] and scores on physical activity measured by LASA Physical Activity Questionnaire (LAPAQ).[@b22-copd-12-2583] LAPAQ is a questionnaire covering several areas of activities. Scores are presented as activity in minutes per day and can be separated into sports and non-sports activities. In addition, participants were asked to maintain a diary card during the whole study period, in which they registered the occurrence of exacerbations and changes in medication. An exacerbation was defined as the presence, for at least 2 consecutive days, of an increase in any two major symptoms (dyspnea, sputum purulence, sputum amount) or an increase in one major and one minor symptom (wheeze, sore throat, cough, symptoms of a common cold).[@b23-copd-12-2583] Finally, quality of life was assessed using the Short Form Health Survey (SF-12)[@b24-copd-12-2583] and EuroQol (EQ-5D) questionnaires.[@b25-copd-12-2583] SF-12 can be subdivided into a physical and mental component summary and is scored within the 0--100 range, with a higher score indicating better quality of life. The EQ-5D score ranges from 0 to 1 with 1 indicating perfect health status.

25(OH)D
-------

Blood samples were drawn from all participants at baseline and after 6 months. Samples were centrifuged and stored at −80°C until determination. After the study was completed, 25(OH)D was assessed in all samples by isotope dilution-solid phase extraction liquid chromatography-tandem mass spectrometry at the Endocrine Laboratory of the VU University Medical Center as described before.[@b26-copd-12-2583] The limit of quantitation was 4.0 nmol/L, intra-assay coefficient of variation (CV) was \<6%, and inter-assay CV was \<8% for concentrations between 25 and 180 nmol/L. 25(OH)D~2~ and 25(OH)D~3~ were measured separately.

Statistical analyses
--------------------

At the start of this study, no trials on the effects of vitamin D supplementation in patients with COPD had been performed. Therefore, there were no data available on which we could base a sample size calculation. Because of the pilot nature of the study, we decided to include 50 participants.

All analyses were performed using the intention-to-treat analysis. In addition, sensitivity analyses including only severe vitamin D-deficient participants (\<25 nmol/L) were performed to assess potential effects in this group. Finally, we also performed a subgroup analysis excluding noncom-pliant participants and participants who had used vitamin D supplementation.

Data are presented as mean ± standard deviation (sd), median (interquartile range) if data were not normally distributed or as number (%). We tested for differences between the placebo and vitamin D group at baseline and for differences between the groups in changes after 6 months. We used an unpaired *t*-test to test for normally distributed continuous variables, Mann--Whitney test for skewed continuous variables, and Pearson *χ*^2^ tests for categorical variables. All analyses were performed using IBM SPSS Statistics for Windows, version 22 (IBM Corporation, Armonk, NY, USA).

Results
=======

We screened 233 patients with COPD for vitamin D deficiency ([Figure 1](#f1-copd-12-2583){ref-type="fig"}). Of these patients, 145 did not meet the inclusion criteria and 38 did not want to participate in the study. Eventually, 50 participants were randomized to receive either placebo (n=26) or vitamin D supplementation (n=24). After randomization, one participant was excluded from the study, because he was wheelchair-bound and could not comply with all the study requirements. During follow-up, six participants withdrew consent.

[Table 2](#t2-copd-12-2583){ref-type="table"} shows the baseline characteristics for both subgroups. Mean serum 25(OH)D levels were deficient in both groups (mean serum 25(OH)D in nmol/L (SD): 42.3 (15.2) and 40.6 (17.0) in the vitamin D and placebo groups, respectively). The placebo group scored slightly better in the 3-meter walking test. No other differences between the groups were detected.

In [Table 3](#t3-copd-12-2583){ref-type="table"}, the differences after 6 months are shown for both groups. The vitamin D group showed a significant increase in serum 25(OH)D levels compared to the placebo group (mean difference (SD): +52.8 (29.8) vs +12.3 (25.1), *P*\<0.001). We did not find any differences between the changes in pulmonary muscle strength and physical performance scores after 6 months. In addition, no differences were found in changes of the secondary outcomes (pulmonary function, handgrip strength, exacerbation rate, or quality of life). Sensitivity analyses in severe vitamin D-deficient participants (n=6) and subgroup analyses excluding noncom-pliant participants (n=9) also did not show any differences (data not shown). A subgroup analysis excluding participants with self-administered vitamin D supplementation also did not show any differences ([Table S1](#SD1-copd-12-2583){ref-type="supplementary-material"}).

No differences were found between the vitamin D group and placebo group after 3 months ([Table S2](#SD2-copd-12-2583){ref-type="supplementary-material"}).

Discussion
==========

This pilot study aimed to assess the effects of vitamin D supplementation on respiratory muscle strength and physical performance in patients with COPD. To the best of our knowledge, this is the first study that has been performed in COPD patients with a vitamin D deficiency. We did not find any effect of vitamin D supplementation on respiratory muscle strength or physical performance. In addition, we did not find any effects on the secondary outcomes -- pulmonary function, hand grip strength, exacerbation rate, and quality of life.

While several observational studies point toward a positive relationship between vitamin D and physical performance in the general population, the number of randomized clinical trials to study a potential causal effect remains very limited. Two trials have assessed the effect of vitamin D supplementation on physical performance in patients with COPD. The first study was a post hoc subgroup analysis of a larger trial assessing the effects of vitamin D supplementation to reduce exacerbations. In this subgroup study, the effects of vitamin D were studied during a rehabilitation program.[@b27-copd-12-2583] Participants (n=50) received a monthly dose of 100,000 IU vitamin D during 3 months. Vitamin D supplementation did not influence physical performance as compared to placebo, although it was related to a slight increase in inspiratory muscle strength. In the second study, participants (n=36) received a daily dose of 2,000 IU vitamin D during 6 weeks. Vitamin D supplementation also did not affect physical performance score in this study.[@b28-copd-12-2583] These findings are in line with our results. Both previous studies did not select patients with vitamin D deficiency at baseline.

Trials assessing the effects of vitamin D supplementation in the general population show conflicting results. One meta-analysis showed no effects of vitamin D supplementation on muscle strength in the general adult population, except in participants with 25(OH)D concentrations \<25 nmol/L at baseline.[@b12-copd-12-2583] Another meta-analysis, including only studies in participants aged ≥60 years, did show an effect on muscle strength and balance.[@b9-copd-12-2583] This might suggest that a potential effect is only relevant in older and vitamin D-deficient participants. This was indeed confirmed in a meta-analysis by Beaudart et al[@b11-copd-12-2583] which showed a larger effect of vitamin D supplementation on global muscle strength in participants with baseline 25(OH)D levels \<30 nmol/L and participants aged \>65 years. A more recent meta-analysis in participants aged ≥65 years, however, did not show an effect of vitamin D supplementation on muscle strength.[@b29-copd-12-2583] A subgroup analysis of participants with serum 25(OH)D \<25 nmol/L in our study did not show any effect. This group, however, was very small (n=6), because we excluded patients with severe vitamin D deficiency (\<15 nmol/L), due to ethical considerations. We also excluded participants aged \>70 years, because the Dutch Health Council recommends vitamin D supplementation in this population. This has led to a lower mean age of our study population compared to other trials.

Two other trials assessing the effects of vitamin D supplementation in COPD have been reported since the start of our study.[@b30-copd-12-2583],[@b31-copd-12-2583] The primary outcome of both studies was exacerbation rate. Both studies did not show an effect of vitamin D supplementation in the total study population, but did find an effect in their subgroup analysis of participants with a (severe) vitamin D deficiency. In our study, we assessed exacerbation rate as a secondary outcome. However, we did not find any differences between the supplementation group and the placebo group. This might be explained by the differences in inclusion criteria. In both the previous studies, participants were included if they had had ≥1 exacerbations in the past year. In our study, however, having an exacerbation in the preceding year was not an inclusion criterion. This might have led to the selection of COPD patients with a milder disease course. As stated earlier, we excluded patients with severe vitamin D deficiency (\<15 nmol/L) in our study, which might have affected our outcomes, as a potential effect of vitamin D supplementation is expected to be stronger in patients with lower vitamin D levels.

A major limitation of our study is the small sample size. As this was considered a pilot trial, we only included 50 participants. This number was chosen as no previous trials were performed on which sample size could be calculated. However, we did not observe any differences which might have reached statistical significance in a larger study population.

Another limitation is the relatively low dose used in our study compared to previous studies. Because the threshold of vitamin D levels for extra-skeletal effects is currently not known, our dose might have been too low to provide a clinical effect. In addition, we used a daily dosing regimen, which leads to more stable levels, but can decrease participants' compliance. However, participants in the supplementation group showed a significant increase in serum 25(OH)D levels, reaching a mean level of 96 nmol/L after 6 months, which is considered sufficient and comparable to levels reached in other studies. A subgroup analysis excluding noncompliant participants did also not affect our results.

To conclude, this trial did not show an effect of vitamin D supplementation on respiratory muscle strength and physical performance. It has shown several factors that can be addressed in future studies. The daily dosing regimen of 1,200 IU might be too low for a clinical effect in patients with COPD. In addition, our study population might have been too good to show a potential effect. Since the start of our study, two other trials assessing the effects of vitamin D supplementation in COPD have been reported.[@b30-copd-12-2583],[@b31-copd-12-2583] These trials did show an effect of vitamin D supplementation on exacerbation rate in subgroups of deficient participants. Therefore, we are currently performing an additional large multicenter trial on the effects of vitamin D supplementation in COPD patients with a vitamin D deficiency ([ClinicalTrials.gov](http://ClinicalTrials.gov), ID number NCT02122627).[@b32-copd-12-2583] Primary outcome in this study is exacerbation rate, but muscle strength and physical performance are secondary outcomes. In this trial, we selected patients that have had an exacerbation in the previous year. In addition, we have increased the supplementation dose to 16,800 IU a week and extended the follow-up to 1 year. This trial is still ongoing and expected to be completed in 2018.

Supplementary materials
=======================

###### 

Differences (Δ) after 6 months with exclusion of participants using vitamin D supplements

                                      Placebo (n=20)            Vitamin D (n=15)          *P*-value
  ----------------------------------- ------------------------- ------------------------- -----------
  Serum 25(OH)D (nmol/L)              +9.1±25.0                 +55.8±32.2                \<0.001
  BMI (kg/m^2^)                       +0.03±0.82                −0.11±0.95                0.645
  Pulmonary function                                                                      
   PEF (L)                            −0.03 \[−0.35 to 0.68\]   +0.08 \[−0.45 to 0.68\]   0.764
   PEF (% predicted)                  +2.60±0.30                +3.39±16.31               0.861
   FEV~1~ (L)                         +0.05 \[−0.08 to 0.30\]   −0.01 \[−0.07 to 0.10\]   0.433
   FEV~1~ (% predicted)               +3.55±8.78                +0.13±4.41                0.143
   FVC (L)                            +0.11±0.29                +0.04±0.19                0.412
   FVC (% predicted)                  +3.70±8.92                +0.29±6.02                0.210
   FEV~1~/FVC                         +1.16±4.76                −0.14±3.22                0.369
  Hand peak flow (L/s)                +5 \[−15 to 49\]          −5 \[−30 to 0\]           0.432
  Respiratory muscle strength (kPa)                                                       
   MIP                                +0.01±1.35                +0.13±1.25                0.805
   MEP                                −0.70±3.00                +0.27±1.89                0.286
  Maximal hand grip strength (kg)     +0.34±4.16                −0.37±2.92                0.581
  SPPB (time in s)                                                                        
   3-meter walking test               +0.0 \[0.0--1.0\]         +0.0 \[−1.0 to 0.0\]      0.049
   Chair stands test                  −1.0 \[−2.0 to 1.0\]      −1.0 \[−2.0 to 0.0\]      0.574
   Tandem test                        +0.46±2.15                −0.45±3.45                0.435
  6-minute walking test (m)           +6.0 \[−22.4 to 58.0\]    −6.0 \[−20.3 to 27.3\]    0.610
  LAPAQ (min/day)                                                                         
   Total activity                     −15±97                    −2±64                     0.655
   Sports activity                    0 \[−16 to 6\]            0 \[−5 to 2\]             0.913
  EQ-5D                               +0.00 \[0.03--0.12\]      +0.00 \[−0.13 to 0.07\]   0.156
  SF-12                                                                                   
   PCS12                              +4.16±7.03                +0.98±7.13                0.232
   MCS12                              +1.38±7.45                −2.15±8.33                0.230
  Number of exacerbations             1 \[0--2\]                0 \[0--2\]                0.507

**Note:** Data are presented as mean ± SD or median \[interquartile range\].

**Abbreviations:** 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; PEF, peak expiratory flow; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure; SD, standard deviation.

###### 

Differences (Δ) after 3 months

                                    Placebo (n=23)            Vitamin D (n=21)         *P*-value
  --------------------------------- ------------------------- ------------------------ -----------
  BMI (kg/m^2^)                     +0.20±0.54                −0.01±0.65               0.250
  Hand peak flow (L/s)              +10 \[−30 to 40\]         +10 \[−33 to 43\]        0.888
  Maximal hand grip strength (kg)   −0.81±4.18                −0.07±2.58               0.484
  SPPB (time in s)                                                                     
   3-meter walking test             +0.0 \[−0.5 to 0.0\]      +0.0 \[−0.8 to 0.0\]     0.739
   Chair stands test                +0.0 \[−1.0 to 1.0\]      +0.0 \[−2.0 to 0.8\]     0.202
   Tandem test                      +0.50±3.79                −0.15±4.08               0.650
  6-minute walking test (m)         +1.9 \[−20.0 to 40.0\]    −2.5 \[−27.5 to 11.4\]   0.358
  LAPAQ (min/day)                                                                      
   Total activity                   −6±82                     +12±99                   0.494
   Sports activity                  0 \[−11 to 0\]            0 \[0--0\]               0.127
  EQ-5D                             +0.00 \[−0.09 to 0.09\]   +0.00 \[0.00--0.06\]     0.991
  SF-12                                                                                
   PCS12                            +3.56±8.40                −1.54±5.32               0.239
   MCS12                            −1.58±8.87                −0.77±9.58               0.781
  Number of exacerbations           0 \[0--1\]                0 \[0--1\]               0.573

**Note:** Data are presented as mean ± SD or median \[interquartile range\].

**Abbreviations:** BMI, body mass index; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; SD, standard deviation.
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###### 

Eligibility criteria

  Inclusion criteria                                                                                               Exclusion criteria
  ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Vitamin D deficiency (serum 25(OH)D \<50 nmol/L)                                                                 Severe vitamin D deficiency (25(OH)D \<15 nmol/L)
  Post-bronchodilator FEV~1~/FVC \<0.70, FEV~1~ \<80% of predicted and COPD diagnosis confirmed by a physician     Clinical suspicion of osteoporosis
  Age 40--70 years                                                                                                 Interfering malignant disease
  Written informed consent                                                                                         Life expectation of \<6 months on the basis of concurrent disease
  Ability to comply with all study requirements                                                                    Pregnant or lactating women, or subjects who intend to become pregnant within the study period
  Potentially unreliable patients and those judged by the investigator to be unsuitable for the study              
  Serious mental impairment, ie, preventing understanding of the study protocol or compliance with the study aim   

**Abbreviations:** 25(OH)D, 25-hydroxyvitamin D; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.

###### 

Baseline characteristics

                                      Placebo (n=26)        Vitamin D (n=24)      *P*-value
  ----------------------------------- --------------------- --------------------- -----------
  Age (years)                         61 \[58--66\]         64 \[61--66\]         0.448
  Gender                                                                          
   Male                               13 (50)               13 (54.2)             0.768
   Female                             13 (50)               11 (45.8)             
  Smoking                                                                         
   Former                             8 (30.8)              6 (25.0)              0.650
   Current                            18 (69.2)             18 (75.0)             
   Pack-years                         30.9±18.5             33.5±20.2             0.627
  BMI (kg/m^2^)                       26.4±5.1              29.6±6.7              0.063
  Serum 25(OH)D (nmol/L)              40.6±17.0             42.3±15.2             0.709
  Serum 25(OH)D \<25 nmol/L           2 (7.7)               4 (16.7)              0.329
  Vitamin D supplementation           7 (27)                6 (25)                0.877
  GOLD stage                                                                      
   I                                  4 (15.4)              6 (25.0)              0.415
   II                                 14 (53.8)             8 (33.3)              
   III                                5 (19.2)              8 (33.3)              
   IV                                 3 (11.5)              2 (8.3)               
  Pulmonary function                                                              
   PEF (L)                            5.47±2.22             4.75±2.46             0.284
   PEF (% predicted)                  73.95±24.71           66.71±27.66           0.333
   FEV~1~ (L)                         1.67 \[1.10--2.16\]   1.51 \[1.21--1.74\]   0.528
   FEV~1~ (% predicted)               58.95±23.03           58.46±21.23           0.938
   FVC (L)                            3.52±1.16             3.37±0.89             0.604
   FVC (% predicted)                  97.08±22.23           98.28±18.72           0.838
   FEV~1~/FVC                         48.46±12.51           48.76±15.01           0.939
  Hand peak flow (L/s)                240 \[190--375\]      235 \[168--291\]      0.417
  Respiratory muscle strength (kPa)                                               
   MIP                                8.27±2.58             7.32±2.36             0.195
   MEP                                12.12±4.36            11.10±3.65            0.390
  Maximal hand grip strength (kg)     34.68±9.86            34.13 (9.92)          0.845
  SPPB (time in s)                                                                
   3-m walking test                   4.5 \[4.0--5.0\]      5.0 \[5.0--6.3\]      0.019
   Chair stands test                  10.0 \[8.8--12.3\]    11.0 \[9.0--13.0\]    0.601
   Tandem test                        7.0 \[3.0--10.0\]     6.0 \[4.0--9.0\]      0.803
  6-minute walking test (m)           416.70±87.15          393.15±92.82          0.375
  LAPAQ (min/day)                                                                 
   Total activity                     174±118               133±83                0.168
   Sports activity                    13 \[0--26\]          0 \[0--17\]           0.530
  EQ-5D                               0.81 \[0.76--0.92\]   0.78 \[0.78--0.84\]   0.402
  SF-12                                                                           
   PCS                                35.07±9.19            38.24±10.55           0.283
   MCS                                53.08±9.10            53.61±7.09            0.831

**Note:** Data are presented as mean ± SD, number (%) or median \[interquartile range\].

**Abbreviations:** 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; PEF, peak expiratory flow; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure.

###### 

Differences (Δ) after 6 months

                                      Placebo (n=24)            Vitamin D (n=19)          *P*-value
  ----------------------------------- ------------------------- ------------------------- -----------
  Serum 25(OH)D (nmol/L)              +12.3±25.1                +52.8±29.8                \<0.001
  BMI (kg/m^2^)                       −0.06±0.96                +0.01±0.93                0.799
  Pulmonary function                                                                      
   PEF (L)                            −0.17 \[−0.40 to 0.58\]   +0.16 \[−0.35 to 0.85\]   0.533
   PEF (% predicted)                  +0.96±10.50               +4.78±15.74               0.346
   FEV~1~ (L)                         +0.05 \[−0.06 to 0.27\]   −0.01 \[−0.07 to 0.10\]   0.255
   FEV~1~ (% predicted)               +3.46±8.05                +0.21±4.25                0.120
   FVC (L)                            +0.11±0.27                +0.05±0.17                0.393
   FVC (% predicted)                  +3.86±8.31                +0.81±5.52                0.176
   FEV~1~/FVC                         +0.99±4.38                −0.34±3.02                0.267
  Hand peak flow (L/s)                +5 \[−15 to 45\]          +0 \[−25 to 35\]          0.685
  Respiratory muscle strength (kPa)                                                       
   MIP                                −0.19±1.45                +0.25±1.22                0.306
   MEP                                −0.35±3.48                +0.51±2.07                0.350
  Maximal hand grip strength (kg)     +0.16±3.89                −0.04±2.73                0.847
  SPPB (time in s)                                                                        
   3-m walking test                   +0.0 \[0.0--1.0\]         +0.0 \[−1.0 to 0.0\]      0.054
   Chair stands test                  +0.0 \[−2.0 to 1.0\]      −1.0 \[−3.0 to 0.0\]      0.189
   Tandem test                        +0.76±2.39                −0.69±3.43                0.180
  6-minute walking test (m)           +14.2 \[−22.4 to 70.5\]   −3.7 \[−19.0 to 27.3\]    0.597
  LAPAQ (min/day)                                                                         
   Total activity                     −22 (94)                  −5 (68)                   0.518
   Sports activity                    0 \[−7 to 6\]             0 \[−5 to 2\]             0.927
  EQ-5D                               +0.00 \[0.00--0.11\]      +0.00 \[−0.14 to 0.04\]   0.080
  SF-12                                                                                   
   PCS12                              +4.06±6.37                +1.14±6.77                0.186
   MCS12                              +1.38±8.49                −1.15±8.41                0.373
  Number of exacerbations             1 \[0--2\]                0 \[0--2\]                0.480

**Note:** Data are presented as mean ± SD or median \[interquartile range\].

**Abbreviations:** 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; PEF, peak expiratory flow; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure; SD, standard deviation.
